Drugs / Florastamin[18F]
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06754085 | Dec 2024 → Jan 2026 overdue | prostate cancer | HTA Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Florastamin[18F] | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06754085 ↗ |
| Modality | Diagnostic / imaging agent | “18F-Florastamin PET/CT imaging” NCT06754085 ↗ |
| Route | Intravenous | “The subjects will be intravenously injected” NCT06754085 ↗ |